efgartigimod PH20 SC — catalyst calendar
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-10-01 in 11d
ESTIMATED |
READOUT
A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcuta
Phase 3 · Primary Immune Thrombocytopenia |
ARGX ARGENX SE | efgartigimod PH20 SC |
ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
|